Search Result

Results for "

cAMP accumulation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (4) Adrenergic Receptor (6) Akt (1) Cannabinoid Receptor (2) CFTR (1) CGRP Receptor (2) CRFR (1) ERK (1) G Protein-coupled Receptor Kinase (GRK) (1) GPR52 (1) GPR84 (1) Isotope-Labeled Compounds (2) mGluR (3) Monoamine Oxidase (1) p38 MAPK (1) PKA (1) PPAR (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (6) Endocrinology (6) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (10)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131032

KI-7	Adenosine Receptor	Others
KI-7 is an A2B adenosine receptor positive allosteric modulator. KI-7 potentiates the cAMP accumulation induced by the non-selective A2B adenosine receptor agonist NECA (EC₅₀=445.8 nM). KI-7 also potentiates the cAMP accumulation induced by the selective A2B adenosine receptor agonist BAY 60-6583 as well as by adenosine with EC₅₀s of 2390 nM and 2550 nM, respectively .

HY-16642A

LY2828360	Cannabinoid Receptor	Neurological Disease
LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB₂) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.

HY-19026

Siguazodan SKF 94836
Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC₅₀ of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC₅₀ of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC₅₀ value of 4.2 μM .

HY-147395

GPR52 agonist-1	GPR52	Neurological Disease
GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC₅₀ value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity .

HY-149933

AM841	Cannabinoid Receptor	Neurological Disease
AM841 is a high-affinity electrophilic ligand. AM841 interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. AM841 reduces Forskolin (HY-15371)-stimulated cAMP accumulation. AM841 also slows gastrointestinal motility .

HY-14302

Salmeterol Maximum Cited Publications 6 Publications Verification GR33343X	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC₅₀s of 9.6, 6.1, and 5.9, respectively .

HY-17453

Salmeterol xinafoate Maximum Cited Publications 6 Publications Verification GR 33343X xinafoate	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC₅₀s of 9.6, 6.1, and 5.9, respectively .

HY-19436

Solabegron 1 Publications Verification GW 427353	Adrenergic Receptor	Metabolic Disease Endocrinology
Solabegron (GW 427353) is a selective β₃-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β₃-AR, with an EC₅₀ value of 22 nM . Solabegron (GW 427353) is being developed for the treatment of overactive bladder and irritable bowel syndrome .

HY-U00341

ST4206	Adenosine Receptor	Neurological Disease
ST4206 is a potent and orally active adenosine A2A receptor antagonist, with K_is of 12 nM and 197 nM for adenosine A2A receptor and adenosine A1 receptor, respectively. ST4206 has the potential for Parkinson׳s disease research .

HY-135119

Salmeterol-d3	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol-d₃ is a deuterium labeled Salmeterol. Salmeterol is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].

HY-124571

ZQ-16	GPR84	Inflammation/Immunology
ZQ-16 is a potent and selective GPR84 agonist with an EC₅₀ value of 0.213 μM. ZQ-16 has no activity on the other free fatty acid receptors (FFARs), including GPR40, GPR41, GPR119 and GPR120 .

HY-156863

GRK2 Inhibitor 2	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
GRK2 Inhibitor 2 (Compound 8h) is a GRK2 inhibitor (IC₅₀: 19 nM). GRK2 Inhibitor 2 also inhibits Aurora-A (IC₅₀: 137 nM). GRK2 Inhibitor 2 promotes β-AR-mediated cAMP accumulation in GRK2-overexpressed HEK293 cells. GRK2 Inhibitor 2 can be used for research of congestive heart failure (HF) .

HY-17453S

Salmeterol-d3 xinafoate GR 33343X-d₃ xinafoate	Isotope-Labeled Compounds Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol-d₃ (xinafoate) is the deuterium labeled Salmeterol xinafoate. Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].

HY-103565

AMN082	mGluR	Neurological Disease
AMN082, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 potently inhibits cAMP accumulation and stimulates GTPγS binding (EC₅₀ values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .

HY-17453S1

Salmeterol-13C6 xinafoate GR 33343X-¹³C₆ xinafoate	Isotope-Labeled Compounds Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol- ¹³C₆ (xinafoate) is the ¹³C₆ labeled Salmeterol (xinafoate). Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.

HY-N2118

Bilobetin 1 Publications Verification	PPAR PKA Akt p38 MAPK ERK	Metabolic Disease
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-P1106

K41498	CRFR	Cardiovascular Disease
K41498 is a potent and highly selective CRF2 receptor antagonist with K_i values of 0.66 nM, 0.62 nM and 425 nM for human CRF_2α, CRF_2β and CRF₁ receptors respectively. K41498 is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF_2α- and hCRF_2β-expressing cells. K41498 can be used for hypotension study .

HY-103565A

AMN082 free base	mGluR	Neurological Disease
AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC₅₀ values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .

HY-100403

Ro 67-7476 Maximum Cited Publications 6 Publications Verification	mGluR	Cancer
Ro 67-7476 is a potent positive allosteric modulator of mGluR₁ and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC₅₀ of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC₅₀=163.3 nM) .

HY-P1106A

K41498 TFA	CFTR	Cardiovascular Disease
K41498 TFA is a potent and highly selective CRF2 receptor antagonist with K_i values of 0.66 nM, 0.62 nM and 425 nM for human CRF_2α, CRF_2β and CRF₁ receptors respectively. K41498 TFA is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF_2α- and hCRF_2β-expressing cells. K41498 TFA can be used for hypotension study .

HY-109139

Taminadenant 1 Publications Verification NIR178; PBF509	Adenosine Receptor	Neurological Disease Cancer
Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A_2A receptor (A_2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with K_B values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response .

HY-120826

A2AAR/hMAO-B-IN-1	Monoamine Oxidase Adenosine Receptor	Neurological Disease
A2AAR/hMAO-B-IN-1 (compoudn 17) is a non-xanthine dual-target inhibitor targeting the A2A adenosine receptor (A2AAR) (IC₅₀: 34.9 nM) andMAO-B (Ki: 39.5 nM, human). A2AAR/hMAO-B-IN-1 inhibits A2AAR-induced cAMP accumulation and exhibits competitive, reversible inhibition of MAO-B. A2AAR/hMAO-B-IN-1 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .

HY-P1471

Adrenomedullin (AM) (22-52), human 22-52-Adrenomedullin (human)	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist, and also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .

HY-P1471A

Adrenomedullin (AM) (22-52), human TFA 22-52-Adrenomedullin (human) (TFA)	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH₂ terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .

Cat. No.	Product Name	Target	Research Area

HY-P4127A

M65 TFA	Peptides	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches .

HY-P1106A

K41498 TFA	CFTR	Cardiovascular Disease
K41498 TFA is a potent and highly selective CRF2 receptor antagonist with K_i values of 0.66 nM, 0.62 nM and 425 nM for human CRF_2α, CRF_2β and CRF₁ receptors respectively. K41498 TFA is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF_2α- and hCRF_2β-expressing cells. K41498 TFA can be used for hypotension study .

HY-P4127

M65	Peptides	Neurological Disease
M65 is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches .

HY-P5950

ACTH (6-24) (human) Adrenocorticotropic hormone (6-24)	Peptides	Cardiovascular Disease
ACTH (6-24) (human) (Adrenocorticotropic hormone (6-24)) is an ACTH fragment. ACTH (6-24) (human) is a competitive inhibitor of steroidogenesis induced by ACTH (1-39) and ACTH (5-24) (K_d:13.4 and 3.4 nM). ACTH (6-24) (human) inhibits corticosterone production and cAMP accumulation induced by hPTH 1-34 .

HY-P1106

K41498	CRFR	Cardiovascular Disease
K41498 is a potent and highly selective CRF2 receptor antagonist with K_i values of 0.66 nM, 0.62 nM and 425 nM for human CRF_2α, CRF_2β and CRF₁ receptors respectively. K41498 is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF_2α- and hCRF_2β-expressing cells. K41498 can be used for hypotension study .

HY-P1471

Adrenomedullin (AM) (22-52), human 22-52-Adrenomedullin (human)	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist, and also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .

HY-P1471A

Adrenomedullin (AM) (22-52), human TFA 22-52-Adrenomedullin (human) (TFA)	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH₂ terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2118

Bilobetin 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Ginkgoaceae Source classification Phenols Polyphenols Metabolic Disease Plants Biflavones Disease Research Fields Ginkgo biloba	PPAR PKA Akt p38 MAPK ERK
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

Cat. No.	Product Name	Chemical Structure

HY-135119

Salmeterol-d3
Salmeterol-d₃ is a deuterium labeled Salmeterol. Salmeterol is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].

HY-17453S

Salmeterol-d3 xinafoate
Salmeterol-d₃ (xinafoate) is the deuterium labeled Salmeterol xinafoate. Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].

HY-17453S1

Salmeterol-13C6 xinafoate
Salmeterol- ¹³C₆ (xinafoate) is the ¹³C₆ labeled Salmeterol (xinafoate). Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

cAMP accumulation

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products